SOLIDSEQ BREAST AND OVARIAN CANCER PANEL (93GENES)

What is Solidseq Breast and Ovarian cancer panel test?

Solidseq Breast and Ovarian cancer panel test a comprehensive genetic test performed on solid tumor tissue (such as biopsy or surgical specimens) from breast or ovarian cancer patients. It analyzes multiple genes known to be involved in the development and progression of breast and ovarian cancers. This test identifies somatic mutations (acquired mutations in the tumor) and sometimes hereditary mutations if present in the tumor DNA.  It uses Next-Generation Sequencing (NGS) technology to provide a detailed molecular profile of the cancer.

Why consider Solidseq Breast and Ovarian cancer panel test?

• To identify genetic mutations driving the tumor's growth.
• To guide targeted therapy options based on the mutation profile.
• To predict response or resistance to specific treatments.
• To assist in prognosis assessment and treatment planning.
• Helps in selecting patients eligible for clinical trials of new targeted therapies.

Who should get tested for Solidseq Breast and Ovarian cancer panel test?

• Patients diagnosed with breast or ovarian cancer requiring molecular characterization of their tumor.
• Individuals who may benefit from personalized targeted therapies.
• Patients with advanced, metastatic, or recurrent disease where treatment options depend on tumor genetics.
• Cases where standard treatments have failed or resistance is suspected.
• Patients being evaluated for clinical trial enrollment based on molecular profile.

More Information

OTHER NAMES: Tumor Tissue Breast and Ovarian Cancer Panel, Solid Tumor Breast/Ovarian Cancer Genetic Panel, NGS Tumor Profiling for Breast and Ovarian Cancer

Breast cancer is the uncontrolled growth of cells in breast tissue, often starting in ducts or lobules. Ovarian cancer originates in the ovaries, fallopian tubes, or peritoneum, often detected late due to subtle symptoms.